Stifel Nicolaus reissued their hold rating on shares of Aratana Therapeutics (NASDAQ:PETX) in a report released on Monday morning. Stifel Nicolaus currently has a $6.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on PETX. Zacks Investment Research cut shares of Aratana Therapeutics from a buy rating to a hold rating in a report on Saturday, November 18th. Lake Street Capital lowered their price objective on shares of Aratana Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a research report on Friday, August 25th. Jefferies Group reaffirmed a buy rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research report on Friday, November 3rd. HC Wainwright initiated coverage on shares of Aratana Therapeutics in a research report on Friday, November 17th. They issued a buy rating and a $10.00 price objective on the stock. Finally, ValuEngine lowered shares of Aratana Therapeutics from a sell rating to a strong sell rating in a research report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Aratana Therapeutics has a consensus rating of Hold and an average price target of $8.55.

Aratana Therapeutics (PETX) opened at $5.38 on Monday. Aratana Therapeutics has a twelve month low of $4.97 and a twelve month high of $8.63. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The business had revenue of $6.16 million for the quarter, compared to analysts’ expectations of $6.47 million. During the same period in the previous year, the company earned ($0.38) earnings per share. The firm’s revenue for the quarter was up 1440.0% compared to the same quarter last year. sell-side analysts expect that Aratana Therapeutics will post -1.03 earnings per share for the current fiscal year.

In related news, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $6.24, for a total transaction of $312,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of the company’s stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $6.53, for a total transaction of $760,849.48. The disclosure for this sale can be found here. Insiders have sold a total of 1,117,032 shares of company stock worth $6,559,891 in the last ninety days. 5.20% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the business. AWM Investment Company Inc. grew its stake in Aratana Therapeutics by 49.4% in the 2nd quarter. AWM Investment Company Inc. now owns 1,587,620 shares of the biopharmaceutical company’s stock worth $11,478,000 after buying an additional 525,000 shares in the last quarter. Teachers Advisors LLC grew its stake in Aratana Therapeutics by 34.5% in the 2nd quarter. Teachers Advisors LLC now owns 72,244 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 18,526 shares in the last quarter. Janney Montgomery Scott LLC grew its stake in Aratana Therapeutics by 7.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 1,200 shares in the last quarter. Williams Jones & Associates LLC purchased a new position in Aratana Therapeutics in the 2nd quarter worth approximately $827,000. Finally, Grandeur Peak Global Advisors LLC grew its stake in Aratana Therapeutics by 40.4% in the 2nd quarter. Grandeur Peak Global Advisors LLC now owns 538,363 shares of the biopharmaceutical company’s stock worth $3,892,000 after buying an additional 155,000 shares in the last quarter. 73.76% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Aratana Therapeutics’ (PETX) “Hold” Rating Reiterated at Stifel Nicolaus” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/21/aratana-therapeutics-petx-hold-rating-reiterated-at-stifel-nicolaus.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.